LTC004 with toripalimab for immunotherapy-resistant solid tumors
Part of Cancer clinical trials.
This trial tests a new combination of two drugs (LTC004 and toripalimab) for people with advanced solid tumors that have stopped responding to standard immunotherapy. It aims to see if this combination can help when immunotherapy alone no longer works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must be between 18 and 75 years old.
- You must have a type of advanced cancer (like lung, cervical, head/neck, or esophageal cancer) that has stopped responding to immunotherapy and you had that immunotherapy for more than 6 months with a good response.
- You must have at least one tumor that can be measured on imaging (CT/MRI).
- You must be in good physical condition (able to do daily activities without help).
- You must not have had more than one prior line of chemotherapy and one line of immunotherapy.
- You must not have untreated brain metastases or other serious health issues like uncontrolled infections or autoimmune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two drugs (LM-108 and toripalimab) for people with advanced solid tumors that have a specific marker called MSI-H or dMMR. It is for those whose cancer has grown after previous immunotherapy treatment.
This trial tests a new combination of two medications (IPG7236 and Toripalimab) for people with advanced solid tumors that have not responded to standard therapies. The goal is to see if the combination is safe and effective.
This trial tests a new investigational drug, TORL-4-500, for people with advanced solid tumors that have not responded to other treatments. It aims to find a safe dose and see if the drug can help shrink or control the cancer.
This study tests a new drug combo (CHS-114 + toripalimab) for people with advanced solid tumors like stomach, esophageal, or colorectal cancer that have already been treated. It aims to see if adding these drugs can help control the cancer better.
This trial tests a new combination of two drugs (AL8326 and Toripalimab) for people with advanced solid tumors that have stopped responding to standard treatments or have no other options. The goal is to see if the combination is safe and shrinks tumors.
This trial tests a new drug that may help people with advanced solid tumors, including liver, stomach, and brain cancers. It is for patients whose cancer has not responded to standard treatments or who cannot have them. The study aims to find the right dose and check safety and effectiveness.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.